Research progress in pathophysiological mechanism and clinical diagnosis and treatment of hypertension associated with vascular endothelial growth factor and its receptor inhibitors
10.13481/j.1671-587X.20240333
- VernacularTitle:血管内皮生长因子及其受体抑制剂相关性高血压病理生理机制及临床诊疗的研究进展
- Author:
Li ZHANG
1
;
Binfeng XIA
;
Huihui HUANG
;
Ru WANG
;
Min KONG
;
Xia YIN
Author Information
1. 吉林大学第一医院心血管内科,吉林 长春 130021
- Keywords:
Antineoplastic drug;
Vascular endothelial growth factors and its receptor inhibitor;
Vascular endothelial growth factor receptor inhibitor;
Cancer therapy-related cardiovascular toxicity;
Hypertension
- From:
Journal of Jilin University(Medicine Edition)
2024;50(3):854-863
- CountryChina
- Language:Chinese
-
Abstract:
Cancer therapy-related cardiovascular toxicity(CTR-CVT)is gradually becoming a critical factor affecting the prognosis of cancer survivors.Vascular endothelial growth factor(VEGF)and its receptor inhibitors(VEGFIs),developed as novel anti-cancer drugs targeting VEGF,are now widely used in clinical practice.They can extend the survival period of the cancer patients and improve the prognosis of the patients.However,the hypertension induced by VEGFIs,as the most common CTR-CVT,may limit and impact their use and leads to severe cardiovascular diseases(CVD).It is essential to closely monitor blood pressure in the cancer patients treated with VEGFIs,conduct early assessments,and optimize the management to achieve the best anti-cancer efficacy and minimize the risk of CTR-CVT.This review discusses the clinical manifestations,pathogenesis,diagnosis,and treatment strategies of VEGFIs-related hypertension,in order to provide better guidances for managing and addressing VEGFIs-related hypertension for the clinicians.
